Dr. Bowser is a Professor and Chair of Neurobiology and a serial entrepreneur. He is co-Founder of Knopp Biosciences, focused on developing drug treatments for neurologic diseases. Knopp signed a parternship deal in 2010 with Biogen Idec for $345 million for a drug targeting ALS (Lou Gehrig’s disease). Dr. Bowser formed Iron Horse Diagnostics in 2012 to market diagnostics and companion biomarkers for ALS and other neurologic diseases.

Dr. Shaw is President of EnCor Biotechnology and long-time collaborator with Dr. Bowser on the discovery and validation of protein biomarkers for neurodegenerative diseases. EnCor is contracted to generate and purify antibodies used in the diagnostic assays developed and marketed by Iron Horse. This important partnership provides a key advantage for Iron Horse versus other competitors in the field that often rely on multiple antibody sources.

Dr. Jeromin has industry experience in the vallidation of disease related biomarkers and generation of clinical diagnostic tests. He has worked in the areas of traumatic brain injury and was recently a Director of a Biotechnology company focused on biomarkers for brain injury and disease.

Dr. Gundel has extensive industry experience from executive management positions at a number of leading biopharmaceutical companies prior to joining Iron Horse Diagnostics. Most recently Dr. Gundel was President and CEO of Amorfix Life Sciences, Chief Scientific Officer at Heat Biologics, the Vice President and Head of Research at Elusys Therapeutics Inc., and Chief Scientific Officer at Arius Research, Inc.

Mike has over 20 years of experience in start-ups, derivative and financial product structuring, regulatory compliance, commercialization and grant production in the life science, technology and Healthcare sectors and was a founding board member of the Arizona Angels investment group.